Phosphoramidite derivatives of gemcitabine for use in the treatment of cancer
Phosphorodiamidate derivatives of e.g. gemcitabine are provided for use in treating cancer. In one embodiment, the two amidate motifs each comprises NR′R″ where R′ is H and R″ is CR 5 R 6 CO 2 R 7 , where R 6 is H, R 5 is the side chain, including H and C 1 , of a naturally occurring alpha amino acid, and R 7 is branched or unbranched, substituted or unsubstituted, acyclic or cyclic alkyl, including t-butyl-CH2-, benzyl and C 3 to C 6 cycloalkyl. Formula (I).
1. A chemical compound having formula I:
wherein:
R 2 is selected from CR 5 R 6 CO 2 R 7 and C 1 -C 6 alkyl and R 1 is selected from H and C 1 -C 6 alkyl, or R 1 and R 2 together with the N atom to which they are attached form a ring moiety consisting of 5 to 8 ring atoms;
R 4 is selected from CR 5 R 6 CO 2 R 7 and C 1 -C 6 alkyl and R 3 is selected from H and C 1 -C 6 alkyl, or R 3 and R 4 together with the N atom to which they are attached form a ring moiety consisting of 5 to 8 ring atoms;
where, independently for each of R 2 and R 4:
R 5 and R 6 are selected, independently, from the side chains of naturally occurring alpha amino acids;
R 7 is selected from C 1 -C 18 alkyl;
Y is selected from H and C(O)R, where R is C 1 -C 18 alkyl; and
Z is selected from H and C(O)R, where R is C 1 -C 18 alkyl,
or a pharmaceutically acceptable salt or crystalline form of a compound of formula I.
2. The compound according to claim 1 , or a pharmaceutically acceptable salt or crystalline form of said compound, where R 2 and R 4 are the same.
3. The compound according to claim 1 , or a pharmaceutically acceptable salt or crystalline form of said compound, where R 2 and R 4 are each CR 5 R 6 CO 2 R 7 .
4. The compound according to claim 1 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein R 7 is selected from branched and unbranched, substituted or unsubstituted, and saturated or unsaturated C 1 -C 18 acyclic alkyl and C 3 -C 8 cyclic alkyl.
5. The compound according to claim 4 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein R 7 is selected from methyl, ethyl, i-propyl, t-butyl-CH 2 —, benzyl and C 3 -C 6 cycloalkyl.
6. The compound according to claim 5 , or a pharmaceutically acceptable salt or crystalline form of said compound, where R 7 is t-butyl-CH 2 —.
7. The compound according to claim 1 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein R 6 is H and R 5 is selected from the side chains of naturally occurring alpha amino acids.
8. The compound according to claim 7 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein R 6 is H and R 5 is selected from H, methyl, i-propyl, —CH 2 Ph, —CH 2 CH(CH 3 ) 2 and —CH(CH 3 )(C 2 H 5 ).
9. The compound according to claim 8 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein R 6 is H and R 5 is methyl.
10. The compound according to claim 9 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein R 7 is selected from methyl, ethyl, i-propyl, t-butyl-CH 2 —, benzyl and C 3 -C 6 cycloalkyl.
11. The compound according to claim 10 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein R 7 is t-butyl-CH 2 —.
12. The compound according to claim 1 , or a pharmaceutically acceptable salt or crystalline form of said compound, where the compound has natural L stereochemistry at *CR 5 R 6 .
13. The compound according to claim 1 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein the compound has D stereochemistry at *CR 5 R 6 .
14. The compound according to claim 1 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein each of R 5 and R 6 is methyl.
15. The compound according to claim 1 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein each of R 1 and R 3 is the same.
16. The compound according to claim 15 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein each of R 1 and R 3 is H.
17. The compound according to claim 16 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein each of R 1 and R 3 is H and each of R 2 and R 4 is CR 5 R 6 CO 2 R 7 .
18. The compound according to claim 17 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein each of R 1 and R 3 is H and each of R 2 and R 4 is CR 5 R 6 CO 2 R 7 wherein R 6 is H and R 5 is selected from the side chains of naturally occurring alpha amino acids.
19. The compound according to claim 18 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein R 5 is selected from H, methyl, i-propyl, —CH 2 Ph, —CH 2 CH(CH 3 ) 2 and —CH(CH 3 )(C 2 H 5 ).
20. The compound according to claim 19 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein R 7 is selected from the group consisting of methyl, ethyl, i-propyl, t-butyl-CH 2 —, benzyl and C 3 -C 6 cycloalkyl.
21. The compound according to claim 1 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein R 1 and R 2 together with the N atom to which they are attached form a ring moiety consisting of 5 to 8 ring atoms and R 3 and R 4 together with the N atom to which they are attached form a ring moiety consisting of 5 to 8 ring atoms.
22. The compound according to claim 1 , or a pharmaceutically acceptable salt or crystalline form of said compound, wherein each of Y and Z is H.
23. A method of treatment of cancer selected from colon cancer, breast cancer, pancreatic cancer, lung cancer and prostate cancer, comprising administering to a patient in need of such treatment an effective dose of a compound according to claim 1 , or a pharmaceutically acceptable salt or crystalline form of said compound.
24. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt or crystalline form of said compound, in combination with a pharmaceutically acceptable carrier, diluent or excipient.
25. A method of preparing a pharmaceutical composition comprising the step of combining a compound according to claim 1 , or a pharmaceutically acceptable salt or crystalline form-of said compound, with a pharmaceutically acceptable excipient, carrier or diluent.
26. A process for preparing a compound of formula I according to claim 1 , the process comprising reacting with phosphoryl chloride (POCl 3 ) a compound of formula (II):
followed by reaction with R 1 R 2 NH and R 3 R 4 NH
wherein
R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R, Y, and Z have the meanings described in claim 1 , wherein when Z is H, the 3′-OH is pre-protected prior to reaction with the POCl 3 and deprotected after reaction with R 1 R 2 NH and R 3 R 4 NH.
27. A compound selected from the group consisting of:
2′-deoxy-2′,2′-difluoro-D-cytidine-5′O-bis(ethoxy-L-alaninyl)-phosphate;
2′-deoxy-2′,2′-difluoro-D-cytidine-5′O-bis(benzoxy-L-alaninyl)-phosphate;
2′-deoxy-2′,2′-difluoro-D-cytidine-5′O-bis(cyclohexoxy-L-alaninyl)-phosphate;
2′-deoxy-2′,2′-difluoro-D-cytidine-5′O-bis(2,2-dimethylpropoxy-L-alaninyl)-phosphate; and
2′-deoxy-2′,2′-difluoro-D-cytidine-5′O-bis(iso-propoxy-L-alaninyl)-phosphate, or a pharmaceutically acceptable salt or crystalline form of said compound.